JP2017513826A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513826A5
JP2017513826A5 JP2016560695A JP2016560695A JP2017513826A5 JP 2017513826 A5 JP2017513826 A5 JP 2017513826A5 JP 2016560695 A JP2016560695 A JP 2016560695A JP 2016560695 A JP2016560695 A JP 2016560695A JP 2017513826 A5 JP2017513826 A5 JP 2017513826A5
Authority
JP
Japan
Prior art keywords
amino acid
group
substituted
composition
aryl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513826A (ja
JP6642887B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023883 external-priority patent/WO2015153761A2/en
Publication of JP2017513826A publication Critical patent/JP2017513826A/ja
Publication of JP2017513826A5 publication Critical patent/JP2017513826A5/ja
Application granted granted Critical
Publication of JP6642887B2 publication Critical patent/JP6642887B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560695A 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック Expired - Fee Related JP6642887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973994P 2014-04-02 2014-04-02
US61/973,994 2014-04-02
PCT/US2015/023883 WO2015153761A2 (en) 2014-04-02 2015-04-01 Macrocyclic peptidomimetics for alpha-helix mimicry

Publications (3)

Publication Number Publication Date
JP2017513826A JP2017513826A (ja) 2017-06-01
JP2017513826A5 true JP2017513826A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6642887B2 JP6642887B2 (ja) 2020-02-12

Family

ID=54241434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560695A Expired - Fee Related JP6642887B2 (ja) 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック

Country Status (6)

Country Link
US (1) US10294273B2 (cg-RX-API-DMAC7.html)
EP (1) EP3126375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6642887B2 (cg-RX-API-DMAC7.html)
CN (1) CN106604928A (cg-RX-API-DMAC7.html)
CA (1) CA2944651A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015153761A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017218560A1 (en) * 2016-06-13 2017-12-21 Google Llc Escalation to a human operator
US10827064B2 (en) 2016-06-13 2020-11-03 Google Llc Automated call requests with status updates
WO2018227053A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Non-chromatographic purification of macrocyclic peptides by a resin catch and release
US11524979B2 (en) 2017-06-15 2022-12-13 University Of Washington Macrocyclic polypeptides
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
WO2019084528A1 (en) * 2017-10-27 2019-05-02 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
JP7167357B2 (ja) 2019-05-06 2022-11-08 グーグル エルエルシー 自動通話システム
US11158321B2 (en) 2019-09-24 2021-10-26 Google Llc Automated calling system
WO2021188126A1 (en) 2020-03-20 2021-09-23 Google Llc Semi-delegated calling by an automated assistant on behalf of human participant
US11303749B1 (en) 2020-10-06 2022-04-12 Google Llc Automatic navigation of an interactive voice response (IVR) tree on behalf of human user(s)
US20250042961A1 (en) * 2021-12-10 2025-02-06 Merck Sharp & Dohme Llc P53 peptidomimetic macrocycles
TW202417465A (zh) 2022-08-23 2024-05-01 日商富士軟片股份有限公司 環肽或其鹽及ｍｄｍｘ抑制劑
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides
US12225158B2 (en) 2022-12-15 2025-02-11 Google Llc System(s) and method(s) for implementing a personalized chatbot
WO2024155627A1 (en) 2023-01-16 2024-07-25 Ambrx, Inc. Anti-cd70 antibody-drug conjugates
AR131133A1 (es) 2023-05-24 2025-02-19 Ambrx Inc INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP1737884B1 (en) * 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
CN105061577A (zh) * 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
WO2009149339A2 (en) * 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
WO2010034032A2 (en) * 2008-09-22 2010-03-25 Aileron Therapeutic, Inc. Methods for preparing purified polypeptide compositions
US9175047B2 (en) * 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010298338A1 (en) * 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
EP2651964B1 (en) * 2010-12-15 2018-02-28 The Research Foundation of State University of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
WO2012100176A2 (en) 2011-01-20 2012-07-26 University Of Rochester Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation

Similar Documents

Publication Publication Date Title
JP2017513826A5 (cg-RX-API-DMAC7.html)
ES2387685T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
US10077294B2 (en) Peptide inhibitors of TEAD/YAP-TAZ interaction
RU2018131636A (ru) Новые конъюгаты аманитина
HRP20120598T1 (hr) Stanično permeabilni peptidni inhibitori jnk signalnog transdukcijskog puta
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
JP2017006120A5 (cg-RX-API-DMAC7.html)
RU2007136026A (ru) Варианты ил-21
JP2019501141A5 (cg-RX-API-DMAC7.html)
MX2020000413A (es) Una vacuna universal basada en neoantigenos de tumor compartidos para prevencion y tratamiento de canceres inestables de microsatelite (msi).
NZ723940A (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
JP2018507689A5 (cg-RX-API-DMAC7.html)
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
CA2432971A1 (en) Polypeptides
MX350220B (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
FI3335725T3 (fi) Pds5a-epitooppeja immuuniteetin indusoijina
CN108452322A (zh) 基于长链非编码rna的bcl2基因抑制剂
CN112739381A (zh) 使用了hsp47的抑制物质的癌转移抑制
EP2545171A4 (en) HJURP PEPTIDES AND VACCINES COMPRISING THEM
EA201291004A1 (ru) Пептиды ect2 и включающие их вакцины
AR113982A1 (es) Péptido antagonista de la actividad de la interleucina-15
AR128014A1 (es) Polipéptidos de penetración celular (cpp) y su uso en terapia humana
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
CN106084009A (zh) 人骨肉瘤u2‑os细胞特异性结合多肽及其应用
MXPA02010813A (es) Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.